Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Telomir Pharmaceuticals, Inc. ( (TELO) ).
Telomir Pharmaceuticals announced that its investigational compound, Telomir-1, has shown efficacy in killing aggressive human leukemia cells in vitro. This finding expands Telomir-1’s oncology profile beyond its previously reported activity in other cancer models, potentially enhancing its relevance in cancer treatment by targeting intracellular iron modulation and epigenetic regulation.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing small-molecule therapies targeting the epigenetic and metabolic roots of cancer, aging, and age-related diseases.
Average Trading Volume: 3,014,120
Technical Sentiment Signal: Sell
Current Market Cap: $49.16M
For an in-depth examination of TELO stock, go to TipRanks’ Overview page.